| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5ad8562c578b061df7a2c3aee9d0e24 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7095 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-163 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
1998-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f49d8df595867ee50f33f2792e08b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41f2b43a8e4c31af61ef45b01e06a7fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffba5b8ac1dfae3d09f099c0d5bb4d8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d126bd934bbfa6bec000e7441f514de3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8feecca52199d9fb535d98712836057c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79359a9e14fb6237746d15f0a4340166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a0a1e89ade30f30e35063ebbcc071d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d010e343cee4a80efd15408ee13413d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1ab1744cb7d8fc674b93a9d0b7b8c2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0b1b1d7c98e0843ea3d1c47fa2cf067 |
| publicationDate |
2000-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20000001629-A |
| titleOfInvention |
Monoclonal antibody against human interleukin18, hybridoma cell line producing same, and method for preparing same |
| abstract |
The present invention relates to a monoclonal antibody against human IL-18 that induces various inflammatory diseases and other intractable diseases in humans, a hybridoma cell line producing the same, and a method for producing the same.n n n The present invention provides a hybridoma cell line by fusion of splenocytes of a mouse immunized with human IL-18 with myeloma cells, and the high specificity of the hybridoma cell line which specifically reacts only with human IL-18 or pro-IL-18 antigen. After screening and screening the bridoma cell line by ELISA assay, the monoclonal antibody produced by mass production of monoclonal antibodies against human IL-18 or pro-IL-18 antigen using the selected hybridomas. Cells expressing IL-18 using these monoclonal antibodies and hybridoma cell lines producing them by antigen-antibody reaction with human IL-18 or pro-IL-18 antigens to confirm that they are specific for IL-18. Can be easily searched, and is useful as a diagnostic and therapeutic agent for inflammatory diseases and intractable diseases caused by IL-18. There are excellent effects for use in clinical diagnostics for inflammatory diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20040075517-A |
| priorityDate |
1998-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |